2020 Update on Sunscreen Compliance With American Academy of Dermatology Recommendations

November 2020 in “ Journal of the American Academy of Dermatology ”

Caiwei Zheng, Siri Choragudi, Shifa Akhtar … Keyvan Nouri

sunscreen American Academy of Dermatology AAD FDA SPF broad-spectrum coverage water resistance tanning bronzing sunblock sun cream

Studysummary Most sunscreens meet safety standards, but tanning products often don't.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on jaad.org →

PubMed
DOI

Discuss this study in the Community →

Similar research 5

Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment American Journal of Clinical Dermatology · 2019
Frontiers In Topical Photoprotection Cosmetics · 2025
Social Media in Dermatology and an Overview of Popular Social Media Platforms Current Dermatology Reports · 2021
Hormonal Therapies in Cosmetic Dermatology: Mechanisms, Clinical Applications, and Future Perspectives Cosmetics · 2025
Liposomes and Other Nanocarriers for the Treatment of Acne Vulgaris: Improved Therapeutic Efficacy and Skin Tolerability Pharmaceutics · 2024

Related Community Posts Join

6 / 31 results

community Minoxidil inhibits lysyl hydroxylase which is needed to produce collagen. If I take 2,5...5 mg of minoxidil every day can I cause my skin to age prematurely?

32 upvotes 1 year ago

Oral minoxidil is effective for hair loss and unlikely to significantly affect collagen synthesis, making it a safe option without causing premature skin aging. Users report positive hair regrowth without noticeable skin aging.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march

30 upvotes 6 months ago

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

122 upvotes 6 months ago

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

community Anyone from Denver gonna go to the Academy of Dermatology Annual Meeting to see Pelage's presentation?

9 upvotes 6 months ago

The conversation discusses attending a presentation by Pelage at the Academy of Dermatology Annual Meeting in Denver, focusing on hair loss treatments. Participants express interest in obtaining information or trial compounds related to hair loss solutions like Minoxidil, finasteride, and RU58841.

community A Short Recap on PP405 and AAD 2026

in Update 5 months ago

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

community Are we still getting the PP405 phase 2a results by the end of March?

32 upvotes 6 months ago

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.